Page 141 - HIV/AIDS Guidelines

infection who requires treatment, clinicians should initiate a regimen containing two NRTIs and a boosted PI.
Monitoring of virologic response in such patients is problematic because of the lack of a commercially
available HIV-2 viral load assay; however, clinical and CD4 count improvement can be used to assess
treatment response.

References
1. Matheron S, Pueyo S, Damond F, et al. Factors associated with clinical progression in HIV-2 infected-patients: the
French ANRS cohort. AIDS. 2003;17(18):2593-2601.
2. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1.
Science. 1994;265(5178):1587-1590.
3. O'Brien TR, George JR, Epstein JS, et al. Testing for antibodies to human immunodeficiency virus type 2 in the United
States. MMWR Recomm Rep. 1992;41(RR-12):1-9.
4. Chan PA, Wakeman SE, Flanigan T, et al. HIV-2 diagnosis and quantification in high-risk patients. AIDS Res Ther.
2008;5:18.
5. Damond F, Benard A, Ruelle J, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral
load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol.
2008;46(6):2088-2091.
6. Gottlieb GS, Eholie SP, Nkengasong JN, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2
infection in West Africa. AIDS. 2008;22(16):2069-2072; discussion 2073-2064.
7. Tuaillon E, Gueudin M, Lemee V, et al. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse
transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr. 2004;37(5):1543-1549.
8. Poveda E, Rodes B, Toro C, et al. Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses.
2004;20(3):347-348.
9. Boyer PL, Sarafianos SG, Clark PK, et al. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?
PLoS Pathog. 2006;2(2):e10.
10. Smith RA, Anderson DJ, Pyrak CL, et al. Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient
for classwide nucleoside analogue resistance. J Infect Dis. 2009;199(9):1323-1326.

11. Parkin NT, Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther.
2004;9(1):3-12.

12. Desbois D, Roquebert B, Peytavin G, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2
clinical isolates to protease inhibitors. Antimicrob Agents Chemother. 2008;52(4):1545-1548.

13. Brower ET, Bacha UM, Kawasaki Y, et al. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.
Chem Biol Drug Des. 2008;71(4):298-305.

14. Rodes B, Sheldon J, Toro C, et al. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing
antiretroviral therapy. J Antimicrob Chemother. 2006;57(4):709-713.
15. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2
clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62(5):914-
920.
16. Owen SM, Ellenberger D, Rayfield M, et al. Genetically divergent strains of human immunodeficiency virus type 2 use
multiple coreceptors for viral entry. J Virol. 1998;72(7):5425-5432.
17. Gottlieb GS, Badiane NM, Hawes SE, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated
individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis. 2009;48(4):476-483.
18. Jallow S, Kaye S, Alabi A, et al. Virological and immunological response to Combivir and emergence of drug resistance
mutations in a cohort of HIV-2 patients in The Gambia. AIDS. 2006;20(10):1455-1458.
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents I-25

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.